XBI — SPDR S&P Biotech ETF
In 2026 Q2, 5 of the 140 tracked hedge funds reported a position in SPDR S&P Biotech ETF (XBI), worth $52.09M combined. Over the quarter 2 opened or added, 2 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Gendell Jeffrey | $41.51M | 0.38% | NO CHANGE |
| Quadrature | $7.12M | 0.06% | -90.7% |
| Amitell | $3.13M | 2.90% | NEW |
| KRS | $266.41K | 0.12% | NO CHANGE |
| Barnes Dennig | $64.09K | 0.05% | +3.1% |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.